India launches first indigenous CRISPR based gene therapy for Sickle Cell Disease | Current Affairs | Vision IAS
MENU
Home

Periodically curated articles and updates on national and international developments relevant for UPSC Civil Services Examination.

Quick Links

High-quality MCQs and Mains Answer Writing to sharpen skills and reinforce learning every day.

Watch explainer and thematic concept-building videos under initiatives like Deep Dive, Master Classes, etc., on important UPSC topics.

ESC

In Summary

India introduces its first indigenous CRISPR-based gene therapy, BIRSA 101, developed by CSIR–IGIB, to treat Sickle Cell Disease, notably affecting India's tribal populations, utilizing innovative genome-editing techniques.

In Summary

The Gene Therapy, named BIRSA 101 is dedicated to Bhagwan Birsa Munda, a great tribal freedom fighter.

  • It is developed by CSIR–Institute of Genomics and Integrative Biology (IGIB)

About Gene Therapy

  • Gene therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder.
  • Working Mechanism: Add new copies of a gene that is broken, or replace a defective or missing gene in a patient’s cells with a healthy version (therapeutic gene) of that gene.

About CRISPR 

  • CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats
  • It is a genome-editing tool that enables scientists to cut and modify DNA sequences precisely.
  • It involves two key molecules
    • Guide RNA: Designed to find and bind to specific parts of the target genome.
    • Cas9 (CRISPR-associated protein 9): It acts as molecular scissors that can cut two strands of DNA.

About Sickle-cell disease (SCD)

  • SCD is a genetic disorder that affects haemoglobin, the molecule in red blood cells responsible for carrying oxygen. 
  • The disease causes red blood cells to become rigid and sickle-shaped, leading to blockages in blood flow. 
  • It particularly affects India's tribal population. (1 in 86 births among STs have SCD)

Related News

enFnCas9

  • An agreement was exchanged between CSIR-IGIB and the Serum Institute of India Pvt. Ltd., to translate enFnCas9 into scalable, affordable therapies for genetic disorders.
  • enFnCas9 (Francisella novicida Cas9 (FnCas9) protein) is an engineered high-fidelity CRISPR-Cas9 platform, developed by IGIB. 
Watch Video News Today

Explore Related Content

Discover more articles, videos, and terms related to this topic

Title is required. Maximum 500 characters.

Search Notes

Filter Notes

Loading your notes...
Searching your notes...
Loading more notes...
You've reached the end of your notes

No notes yet

Create your first note to get started.

No notes found

Try adjusting your search criteria or clear the search.

Saving...
Saved

Please select a subject.

Referenced Articles

linked

No references added yet